Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 3/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792494 | 0.87 | TYK2 (0.42) | GPR35MRGPRX4TYK2PDK1PDK2 | |
| SCHEMBL21826384 | 0.87 | ALDH1A1 (0.44) | GPR35MRGPRX4TYK2FLT1FLT4 | |
| SCHEMBL792787 | 0.83 | ALDH1A1 (0.46) | GPR35MRGPRX4TYK2TAS1R3TAS1R1 | |
| SCHEMBL7016991 | 0.81 | GPR35 (0.41) | GPR35TYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21972198 | 0.78 | PTGS1 (0.43) | TYK2DPP4AKR1C2AKR1C1TTR | |
| SCHEMBL1707633 | 0.76 | MRGPRX4 (0.45) | GPR35MRGPRX4TYK2TAS1R3TAS1R1 | |
| SCHEMBL4849457 | 0.76 | GPR35 (0.42) | GPR35MRGPRX4VCAM1TTRALB | |
| SCHEMBL31013970 | 0.76 | CA12 (0.44) | GPR35TTRALBMEN1KMT2A | |
| SCHEMBL794012 | 0.75 | TYK2 (0.45) | GPR35TYK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL27816654 | 0.75 | AKR1C2 (0.41) | GPR35MRGPRX4AKR1C2AKR1C1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| CN-102459187-A | Janus Kinase Inhibiting Compounds and Methods | HOFFMANN LA ROCHE | 2012-05-16 | — | — | CN | disclosed |
| EP-2440529-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7759388-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20090048236-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO. INC (JP) | 2009-02-19 | — | — | US | disclosed |
| US-7452905-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-11-18 | — | — | US | disclosed |
| EP-1323711-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2006-11-15 | — | — | EP | disclosed |
| US-20030220318-A1 | New phenylalanine derivatives | AJINOMOTO CO. INC (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1323711-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220318-A1 | New phenylalanine derivatives | VCAM1, PAH, ICAM1 | GPR35 488/4885MRGPRX4 441/4885TYK2 121/4885 |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | GPR35 1246/4885MRGPRX4 2238/4885TYK2 596/4885 |
| US-20090048236-A1 | NEW PHENYLALANINE DERIVATIVES | ITGB4, VCAM1, ITGA4 | GPR35 549/4885MRGPRX4 181/4885TYK2 184/4885 |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | GPR35 978/4885MRGPRX4 1962/4885TYK2 2291/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | GPR35 2960/4885MRGPRX4 1009/4885TYK2 21/4885 |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | GPR35 978/4885MRGPRX4 1962/4885TYK2 2291/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | GPR35 1152/4885MRGPRX4 2513/4885TYK2 732/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | GPR35 1152/4885MRGPRX4 2513/4885TYK2 732/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | GPR35 1152/4885MRGPRX4 2513/4885TYK2 732/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | GPR35 978/4885MRGPRX4 1962/4885TYK2 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.